Trump Signals Federal Cannabis Reclassification Push

President-elect Donald Trump has indicated his administration will pursue moving marijuana to a lower federal risk classification, signaling potential acceleration of the rescheduling process currently stalled in regulatory review. The announcement comes as the cannabis industry awaits final action on the Biden administration's proposed move from Schedule I to Schedule III under the Controlled Substances Act.

The rescheduling initiative carries substantial financial implications for multi-state operators currently facing effective tax rates exceeding 70% due to Section 280E restrictions. Schedule III classification would allow standard business deductions, potentially improving EBITDA margins by 15-25 percentage points for major operators like Curaleaf, Green Thumb Industries, and Trulieve Cannabis.

Trump's position marks a notable shift from his previous administration's cannabis stance, reflecting evolving political dynamics as 38 states now operate legal cannabis programs. The regulatory change would not federally legalize marijuana but would remove significant tax burdens while maintaining state-level control over recreational and medical programs.

Cannabis equity valuations remain compressed compared to traditional consumer goods companies, trading at enterprise value-to-sales multiples of 2-4x versus 6-8x for comparable CPG businesses. Federal rescheduling could narrow this valuation gap by reducing regulatory uncertainty and enabling institutional investment from funds restricted by federal scheduling.

The timeline for implementation remains unclear, as rescheduling requires completion of the DEA's review process and final rule publication. However, Trump's explicit support could expedite bureaucratic procedures that have delayed progress under the current administration, potentially delivering the regulatory catalyst the cannabis sector has anticipated since the initial HHS recommendation in August 2023.